Table 3.

Subsequent lines of therapy

	n (%)
Second-line therapy
Fluoropyrimidines	4 (15)
Irinotecan	11 (42)
Platin*	10 (38)
Taxane	3 (11.5)
Paclitaxel-ramucirumab	0
Checkpoint inhibitors	3 (11.5)
Trastuzumab	12 (46)
Other	3 (11.5)
Third-line therapy
Fluoropyrimidines	6 (23)
Irinotecan	4 (15)
Platin*	9 (35)
Taxane	2 (8)
Paclitaxel-ramucirumab	1 (4)
Checkpoint inhibitors	2 (8)
Trastuzumab	8 (31)
Other	1 (4)
Fourth-line therapy
Fluoropyrimidines	1 (4)
Irinotecan	0
Platin*	1 (4)
Taxane	0
Paclitaxel-ramucirumab	1 (4)
Checkpoint inhibitors	0
Trastuzumab	2 (8)
Other	1 (4)

^*Includes cisplatin, carboplatin and oxaliplatin